Clinical Trial Update: A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease [Phase 3]

View source ↗

Summary

Phase 3 open-label trial evaluating AA4500 given in two monthly doses per cycle over up to four cycles for Peyronie's disease; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peyronie Disease

Drugs mentioned

• AA4500

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Peyronie's Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-04-07